Physician profile
Randall C Fedro
NPI 1265443550
$11,782.18
in general payments reported to CMS, 2019-2025
58 companies · $52.88 in 2025
The $52.88 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,427 · 2020: $1,290 · 2021: $2,052 · 2022: $2,346 · 2023: $2,861 · 2024: $1,754 · 2025: $52.88.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,644 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,643.53 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,729.32 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $1,441.94 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,084.27 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $808.72 | 2019-2024 | Mounjaro, Emgality, Zepbound |
| Glaxosmithkline, LLC. | $675.33 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Pfizer INC. | $604.93 | 2019-2024 | |
| Amgen INC. | $440.25 | 2019-2024 | Otezla, Repatha |
| Otsuka America Pharmaceutical, INC. | $422.81 | 2022-2024 | Rexulti, Abilify Maintena |
| Axsome Therapeutics, INC. | $386.61 | 2022-2024 | Sunosi |
| Janssen Pharmaceuticals, INC | $366.76 | 2019-2023 | Xarelto |
| Abbott Laboratories | $321.35 | 2021-2024 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $291.86 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $285.16 | 2022 | |
| Merck Sharp & Dohme LLC | $249.68 | 2019-2024 | Gardasil 9, Vaxelis, Gardasil |
| Biohaven Pharmaceuticals, INC. | $221.07 | 2020-2021 |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randall Fedro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.